Field Randomization of NA-1 Therapy in Early Responders
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether NA-1 is effective in reducing global
disability in patients with acute cerebral ischemia if administered early after symptom
onset.
Phase:
Phase 3
Details
Lead Sponsor:
NoNO Inc.
Collaborators:
Brain Canada Canadian Stroke Network Dalhousie University Djavad Mowafaghian Centre for Brain Health Genome British Columbia St. Michael's Hospital, Toronto Sunnybrook Health Sciences Centre Trillium Health Centre University Health Network, Toronto University of British Columbia University of Calgary University of Toronto Vancouver General Hospital